dr. farago on effectiveness of single-agent lurbinectedin in sclc
Published 4 years ago • 1.5K plays • Length 2:50Download video MP4
Download video MP3
Similar videos
-
1:41
dr. farago on eligibility criteria for frontline immunotherapy in sclc
-
1:45
dr. farago on combination of olaparib and temozolomide in small cell lung cancer
-
1:09
dr. farago on opportunities to investigate biomarkers for small cell lung cancer
-
4:18
lurbinectedin’s role in managing sclc
-
0:35
dr. farago on the fda approval of pembrolizumab for lower pd-1 cutoff nsclc
-
1:54
dr. forster on next steps with lurbinectedin in sclc
-
2:00
dr. west on lurbinectedin in sclc
-
1:28
dr. forster on recent data with lurbinectedin in sclc
-
6:37
caspian trial: durvalumab and chemotherapy in es-sclc
-
1:59
dr. lai on the results of the caspian trial in small cell lung cancer
-
0:48
immunotherapy for patients with small-cell lung cancer
-
4:27
emerging treatment options for sclc
-
3:00
small-cell lung cancer: future directions in care
-
7:39
data on fda approved therapy for relapsed/refractory sclc
-
5:27
asco 2021 lung recap: lurbinectedin in small cell lung cancer and the failed atlantis trial
-
1:44
dr. liu on the checkmate-032 trial in sclc
-
6:33
a win for small–cell lung cancer: impower 133
-
0:50
efficacy and safety of lurbinectedin in elderly patients with relapsed sclc
-
1:10
dr. patel on immunotherapy landscape of stage iv nsclc